Cancer as a Hidden Catalyst: Rethinking Postoperative Atrial Fibrillation After Cardiac Surgery
Journal of Clinical Medicine · 09.06.2026 · 15 (12) · 4456
DOI: 10.3390/jcm15124456 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 09.06.2026. Verfasst von Sotiris Kyriakou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AD, UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Postoperative atrial fibrillation (POAF) is the most frequent post-cardiac surgical arrhythmia and is associated with haemodynamic instability, longer hospital stays, higher healthcare utilisation, stroke and adverse long-term outcomes. Conventional models of POAF focus on advancing age, pre-existing atrial substrate, increasing operative complexity, inflammatory responses related to cardiopulmonary bypass, disturbances in autonomic balance, and acute metabolic insults during the perioperative period. Although these explanations are important, they may be incomplete. Malignancy and the cancer-associated systemic environment involve biological processes potentially relevant to postoperative atrial vulnerability, such as chronic inflammation, oxidative stress, impaired vascular function, hypercoagulability, altered immune response, frailty, and treatment-related myocardial, pericardial, or conduction-system injury. This review assesses whether malignancy should be regarded as an underrecognised modifier of susceptibility rather than as a coincidental comorbidity. Most available data are extrapolated from cardio-oncology and thoracic oncology studies or general studies related to atrial fibrillation (AF) rather than studies focused on cardiac surgery. While malignancy cannot be dismissed as irrelevant to the generation of POAF, it also does not permit causal inference. Future studies should move beyond binary cancer status and incorporate cancer activity, treatment exposures, biomarker profiles, and atrial substrate measures to determine whether malignancy improves perioperative POAF risk stratification.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AD, UK.
- School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.
- Department of Cardiology, Marien Hospital Düsseldorf, 40479 Düsseldorf, Germany.
- Barking, Havering and Redbridge University Hospitals NHS Trust, London RM1 2BA, UK.
- Faculty of Medicine & Surgery, University of Turin, 10126 Turin, Italy.
- Department of Surgery, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
ORCID-Profile: Sotiris Kyriakou, Panos Georghiou, Filippos Triposkiadis, Argyris Kyriakou, Georgios P Georghiou
Zitieren
APA
Kyriakou, S., Markantonis, M., Georghiou, P., Triposkiadis, F., Georgiou, A., Lampropoulos, K., Kyriakou, A., Iosif, N., & Georghiou, G. P. (2026). Cancer as a Hidden Catalyst: Rethinking Postoperative Atrial Fibrillation After Cardiac Surgery. Journal of Clinical Medicine, 15(12), 4456. https://doi.org/10.3390/jcm15124456
Vancouver
Kyriakou S, Markantonis M, Georghiou P, Triposkiadis F, Georgiou A, Lampropoulos K, et al. Cancer as a Hidden Catalyst: Rethinking Postoperative Atrial Fibrillation After Cardiac Surgery. Journal of Clinical Medicine. 2026;15(12):4456. doi:10.3390/jcm15124456
BibTeX
@article{Kyriakou2026,
author = {Kyriakou, Sotiris and Markantonis, Marios and Georghiou, Panos and Triposkiadis, Filippos and Georgiou, Amalia and Lampropoulos, Konstantinos and Kyriakou, Argyris and Iosif, Nikolas and Georghiou, Georgios P},
title = {Cancer as a Hidden Catalyst: Rethinking Postoperative Atrial Fibrillation After Cardiac Surgery},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {12},
pages = {4456},
doi = {10.3390/jcm15124456}
}
EUVIMED